Acorda Therapeutics Inc., of Ardsley, N.Y., reported Ampyra (dalfampridine) extended-release tablets, 10 mg, indicated to help improve walking in adults with multiple sclerosis (MS), achieved net revenue of $167.2 million for the quarter ending Dec. 31, 2017, compared to $132.3 million for the same quarter in 2016.